Clinical trialNCT04300920CompletedPhase 3Interventional

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

SponsorFernando J MartinezEnrollment202Idiopathic Pulmonary Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard care with matched placebo plus standard of care in patients diagnosed with idiopathic pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function \[10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or all-cause mortality\] The secondary objectives will be to examine the effect of NAC on the components of the primary composite endpoint, the rates of clinical events, change in physiology, change in health status, and change in respiratory symptoms.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Cathie Spino, ScD
University of Michigan
Principal Investigator
clinicaltrials.gov ↗
Fernando J Martinez, MD
University of Massachusetts, Worcester
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Imre Noth, MD
University of Virginia
Principal Investigator
clinicaltrials.gov ↗
Kevin Flaherty, MS, MD
University of Michigan
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arizona
Tucson, Arizona, United States
University of Southern California
Los Angeles, California, United States
Stanford University
Stanford, California, United States
University of Colorado
Aurora, Colorado, United States
Piedmont Healthcare
Austell, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Loyola University
Maywood, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Tulane University
New Orleans, Louisiana, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Weill Cornell Medicine
New York, New York, United States
University of Rochester
Rochester, New York, United States
Ohio State University
Columbus, Ohio, United States
Temple University
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Lisa Lancaster
Nashville, Tennessee, United States
University of Texas Southwestern
Dallas, Texas, United States
University of Texas Health San Antonio
San Antonio, Texas, United States
University of Utah Health
Salt Lake City, Utah, United States
University of Virginia
Charlottesville, Virginia, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Acetylcysteine →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Dec 2020
Primary completion: 2 Mar 2026
Completion: 2 Mar 2026
Last update posted: 20 Mar 2026
Registered enrollment: 202
Registry id: NCT04300920

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.